Cornerstone Specialty Network, LLC reported that the FDA approved Iberdomide (Zenbexus) plus daratumumab and dexamethasone for relapsed/refractory multiple myeloma on August 13, 2026.

Cornerstone aggregates the purchasing power and structures of independent, community oncology practice to deliver value that a practice could not otherwise achieve on its own. Cornerstone Specialty Network provides long-term, sustainable value through an aggregated network of Community Oncology practices. Founded in 2016, CSN’s mission is to provide value to Community Oncology practices in order to help maximize the quality of patient care. Through network aggregation, CSN delivers value added opportunities that support independence and long-term sustainability for community oncology practices. We negotiate optional, contracted services on behalf of the network. The mission is built on these four pillars: INDEPENDENCE Supporting independence for Community Oncology practices. POWER Aggregating group purchasing power to bring significant, bottom-line growth to network members. VALUE Providing services that help diversify income sources and increase practice efficiency. SUPPORT Delivering best practices, benchmarking metrics, market data and peer consulting services. As a Cornerstone Partner Practice, access to aggregated services and offers include: 1. Access to a best-in-class, aggregated Distribution/GPO opportunity exclusive to members of The Oncology Network of Excellence™ (TheONE™) 2. Exclusive diagnostic contracts 3. Real estate services and consolidation models 4. Aggregated clinical trial participation opportunities 5. Creating revenue opportunities based on compliant practice data 6. Forums for business best practice sharing 7. Market research participation